Therapeutics Company Secures $5.8 Private Placement For Cancer Therapy Project

MiNK Therapeutics, Inc. (NASDAQ: INKT), a company in the biopharmaceutical sector, has announced an essential milestone in its quest to revolutionize cancer treatment. With a focus on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases, MiNK has entered into a stock purchase agreement to raise $5.8 million through a private placement financing (PIPE). This crucial influx of capital is designated to expedite the clinical trials of MiNK-215, the company's flagship allogeneic CAR-iNKT cell therapy, targeting fibroblast activation protein (FAP) in solid tumors, with an anticipated clinic entry in early 2025. $MiNK Therapeutics (INKT.US)$